Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials

Journal of Nutrition

Volumn 143, Issue 8, 2013, Pages 1263-1268

  Gluud, Lise L ^a   Dam, Gitte ^b   Borre, Mette ^b   Les, Ĩigo ^c   Cordoba, Juan ^c   Marchesini, Giulio ^d   Aagaard, Niels K ^b   Risum, Niels ^a   Vilstrup, Hendrik ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRANCHED CHAIN AMINO ACID; PLACEBO;

ALCOHOL LIVER DISEASE; ARTICLE; COCHRANE LIBRARY; DRUG EFFECT; EMBASE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HUMAN; INFORMED CONSENT; LIVER CIRRHOSIS; MEDLINE; META ANALYSIS; NITROGEN BALANCE; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PATIENT CODING; PROFESSIONAL STANDARD; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SCISEARCH; SYSTEMATIC REVIEW; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT DURATION; VIRUS HEPATITIS;

ADMINISTRATION, ORAL; AMINO ACIDS, BRANCHED-CHAIN; DIETARY SUPPLEMENTS; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84881361645     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.113.174375     Document Type: Article

References (40)

1. Blei AT, Cordoba J. Hepatic encephalopathy. Am J Gastroenterol. 2001;96:1968-76.
2. Bajaj JS. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol. 2008;14:3609-15.
3. Fichet J, Mercier E, Genee O, Garot D, Legras A, Dequin PF, Perrotin D. Prognosis and 1-year mortality of intensive care unit patients with severe hepatic encephalopathy. J Crit Care. 2009;24:364-70.
4. Jepsen P, Ott P, Andersen PK, Sorensen HT, Vilstrup H. Clinical course of alcoholic liver cirrhosis: a Danish population-based cohort study. Hepatology. 2010;51:1675-82
5. Wright G, Jalan R. Management of hepatic encephalopathy in patients with cirrhosis. Best Pract Res Clin Gastroenterol. 2007;21:95-110.
6. Garcĺia-Martĺinez R, Cordoba J. Acute-on-chronic liver failure: the brain. Curr Opin Crit Care. 2011;17:177-83.
7. Fischer JE. Branched-chain-enriched amino acid solutions in patients with liver failure: an early example of nutritional pharmacology. JPEN J Parenter Enteral Nutr. 1990;14:S249-56.
8. Holecek M. Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition. 2010;26:482-90.
9. Bak LK, Schousboe A, Waagepetersen HS. The glutamate/GABAglutamine cycle: aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 2006;98:641-53.
10. Bak LK, Waagepetersen HS, Sorensen M, Ott P, Vilstrup H, Keiding S, Schousboe A. Role of branched chain amino acids in ammonia homeostasis related to hepatic encephalopathy. Metab Brain Dis. 2013;28: 209-15.
11. Dam G, Keiding S, Munk OL, Ott P, Buhl M, Vilstrup H, Bak LK, Waagepetersen HS, Schousboe A, Moller N, et al. Branched-chain amino acids increase arterial blood ammonia in spite of enhanced intrinsic muscle ammonia metabolism in patients with cirrhosis and healthy subjects. Am J Physiol Gastrointest Liver Physiol. 2011;301:G269-77.
12. Kachaamy T, Bajaj JS. Diet and cognition in chronic liver disease. Curr Opin Gastroenterol. 2011;27:174-9.
13. Als-Nielsen B, Koretz RL, Kjaergard LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst Rev. 2003;CD001939.
14. Koretz RL, Avenell A, Lipman TO. Nutritional support for liver disease. Cochrane Database Syst Rev. 2012;5:CD008344.
15. Muto Y, Sato S, Watanabe A, Moriwaki H, Suzuki K, Kato A, Kato M, Nakamura T, Higuchi K, Nishiguchi S, et al. Effects of oral branchedchain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3:705-13.
16. Marchesini G, Bianchi G, Merli M, Amodio P, Panella C, Loguercio C, Rossi Fanelli F, Abbiati R. Nutritional supplementation with branchedchain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124:1792-801.
17. Les I, Doval E, Garcia-Martinez R, Planas M, Cardenas G, Gomez P, Flavia M, Jacas C, Minguez B, Vergara M, et al. Effects of branchedchain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. Am J Gastroenterol. 2011;106:1081-8.
18. Gluud LL, Dam G, Borre M, Les I, Cordoba J, Marchesini G, Aagaard NK, Vilstrup H. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: what is the evidence? Metab Brain Dis. 2013; 28:221-5.
19. Cochrane Handbook for Systematic Reviews of Interventions [cited 2013 Mar 5]. Available from: http://handbook.cochrane.org.
20. Moher D, Altman DG, Liberati A, Tetzlaff J. PRISMA statement. Epidemiology. 2011;22:128.
21. Marchesini G, Dioguardi FS, Bianchi GP, Zoli M, Bellati G, Roffi L, Martines D, Abbiati R. Long-term oral branched-chain amino acid treatment in chronic hepatic encephalopathy. A randomized doubleblind casein-controlled trial. The Italian Multicenter Study Group. J Hepatol. 1990;11:92-101
22. Savovic J, Jones HE, Altman DG, Harris RJ, Juni P, Pildal J, Als-Nielsen B, Balk EM, Gluud C, Gluud LL, et al. Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. Ann Intern Med. 2012;157:429-38.
23. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials. 2005;2:209-17.
24. Identifying and measuring heterogeneity. Cochrane Handbook for Systematic Reviews of Interventions [cited 2013 Mar 5]. Available from: http://handbook.cochrane.org/
25. Higgins JP, Whitehead A, Simmonds M. Sequential methods for random-effects meta-analysis. Stat Med. 2011;30:903-21.
26. Egberts EH, Schomerus H, Hamster W, Jurgens P. Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double-blind placebo-controlled crossover study. Gastroenterology. 1985;88:887-95.
27. Hayashi SAY, Fujiwara K, Oda T. A randomized controlled trial of branched-chain amino acid (BCAA)-enriched elemental diet (ED-H) for hepatic encephalopathy. J Gastroenterol Hepatol. 1991;6:91.
28. Horst D, Grace ND, Conn HO, Schiff E, Schenker S, Viteri A, Law D, Atterbury CE. Comparison of dietary protein with an oral, branched chain-enriched amino acid supplement in chronic portal-systemic encephalopathy: a randomized controlled trial. Hepatology. 1984;4: 279-87.
29. Plauth M, Egberts EH, Hamster W, Torok M, Muller PH, Brand O, Furst P, Dolle W. Long-term treatment of latent portosystemic encephalopathy with branched-chain amino acids. A double-blind placebocontrolled crossover study. J Hepatol. 1993;17:308-14.
30. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy: definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11thWorld Congresses of Gastroenterology, Vienna, 1998. Hepatology. 2002;35:716-21.
31. Bianchi G, Giovagnoli M, Sasdelli AS, Marchesini G. Hepatic encephalopathy and health-related quality of life. Clin Liver Dis. 2012;16: 159-70.
32. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010;362:1071-81.
33. Albillos A. Preventing first variceal hemorrhage in cirrhosis. J Clin Gastroenterol. 2007;41 Suppl 3:S305-11.
34. Abraldes JG, Bosch J. The treatment of acute variceal bleeding. J Clin Gastroenterol. 2007;41 Suppl 3:S312-7.
35. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53: 397-417.
36. Hutson SM, Sweatt AJ, Lanoue KF. Branched-chain [corrected] amino acid metabolism: implications for establishing safe intakes. J Nutr. 2005;135:S1557-64.
37. Sanyal A, Younossi ZM, Bass NM, Mullen KD, Poordad F, Brown RS, Vemuru RP, Mazen Jamal M, Huang S, Merchant K, et al. Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy - a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2011;34:853-61.
38. Plauth M, Cabre E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, Ferenci P, Holm E, Vom Dahl S, Muller MJ, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006;25:285-94.
39. Kakazu E, Ueno Y, Kondo Y, Fukushima K, Shiina M, Inoue J, Tamai K, Ninomiya M, Shimosegawa T. Branched chain amino acids enhance the maturation and function of myeloid dendritic cells ex vivo in patients with advanced cirrhosis. Hepatology. 2009;50:1936-45.
40. Nakamura I, Ochiai K, Imai Y, Moriyasu F, Imawari M. Restoration of innate host defense responses by oral supplementation of branchedchain amino acids in decompensated cirrhotic patients. Hepatol Res. 2007;37:1062-7.